Results 1 to 10 of about 5,287 (115)

Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis

ENeurologicalSci, 2018
Background and purpose: Oxidative stress has been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). Edaravone, a free radical scavenger, was approved as a therapeutic drug for ALS in 2015 in Japan.
Yukio Ando, Satoshi Yamashita, Masatoshi Ishizaki   +2 more
exaly   +3 more sources

Cost-effectiveness of edaravone dexborneol versus edaravone for the treatment of acute ischemic stroke in China: Based on the TASTE study

Frontiers in Pharmacology, 2022
Background and purpose: The TASTE trial indicated that patients with acute ischemic stroke (AIS) using edaravone dexborneol have a significantly higher proportion of 90-day good functional outcomes (mRS 0–1) than those using edaravone.
Sheng Han, Shi Fenghao
exaly   +3 more sources

Safety assessment of Edaravone: A real-world adverse event analysis based on the FAERS Database. [PDF]

PLoS ONE
ObjectiveEdaravone is a neuroprotective agent, but the characteristics of its adverse events (AEs) remain insufficiently explored. This study aims to examine AEs associated with edaravone use by analyzing real-world data from the FDA Adverse Event ...
Ziyue Wang, Bowen Lu, Hao Yang, Weijie Zhao, Xinru Kong, Chuanhao Mi, Jianlin Wu   +6 more
doaj   +2 more sources

Edaravone Dexborneol in acute ischemic stroke patients treated with combined intravenous thrombolysis and mechanical thrombectomy for large vessel occlusion [PDF]

Frontiers in Neurology
BackgroundMechanical thrombectomy (MT), when combined with intravenous thrombolysis (IVT), has emerged as an effective therapeutic strategy for acute ischemic stroke (AIS).
Bo Peng, Ruilong Wang, Wei Jiang, Mo Zou, Hao Li, Hongxu Zhang   +5 more
doaj   +2 more sources

Edaravone efficacy in amyotrophic lateral sclerosis with reduced forced vital capacity: Post-hoc analysis of Study 19 (MCI186-19) [clinical trial NCT01492686]

PLoS ONE, 2022
Background Edaravone slowed the rate of functional decline in subjects with amyotrophic lateral sclerosis (ALS) in phase 3 study MCI186-19 (Study 19).
Benjamin Rix Brooks, Terry Heiman-Patterson, Martina Wiedau-Pazos, Shawn Liu, Jeffrey Zhang, Stephen Apple   +5 more
doaj   +2 more sources

Renoprotective Effects of Edaravone in a Model of Acute kidney Injury Induced by Rhabdomyolysis in Rats, the Involvement of Nitric oxide [PDF]

Trends in Pharmaceutical Sciences, 2022
Edaravone is a free radical scavenger which is used as a drug for the treatment of cerebral infarction and amyotrophic lateral sclerosis. Edaravone is distributed widely in the body and its effects are not limited to the neural tissue.
Leila Moezi, Mohammad Reza Panjehshahin, Simin Torabinezhad, Eskandar Kamali-Sarvestani, Shirin Farjadian, Fatema Pirsalami, Azin Ebrahimpour, Somayeh Oftadehgan, Azar Purkhosrow, Maryam Mojahedtaghi, Elahe Sattarinezhad   +10 more
doaj   +1 more source

Edaravone Attenuated Angiotensin II-Induced Atherosclerosis and Abdominal Aortic Aneurysms in Apolipoprotein E-Deficient Mice

Biomolecules, 2022
Background: The aim of the study was to define whether edaravone, a free-radical scavenger, influenced angiotensin II (AngII)-induced atherosclerosis and abdominal aortic aneurysms (AAAs) formation.
Haruhito A. Uchida, Tetsuharu Takatsuka, Yoshiko Hada, Ryoko Umebayashi, Hidemi Takeuchi, Kenichi Shikata, Venkateswaran Subramanian, Alan Daugherty, Jun Wada   +8 more
doaj   +1 more source

Edaravone Modulates Neuronal GPX4/ACSL4/5-LOX to Promote Recovery After Spinal Cord Injury

Frontiers in Cell and Developmental Biology, 2022
The FDA-approved drug edaravone has a neuroprotective effect on spinal cord injury (SCI) and many other central nervous system diseases. However, its molecular mechanism remains unclear.
Yilin Pang, Xinjie Liu, Xu Wang, Xuelian Shi, Lei Ma, Yan Zhang, Tiangang Zhou, Chenxi Zhao, Xu Zhang, Baoyou Fan, Jian Hao, Wenxiang Li, Xiaoqing Zhao, Rong Zhang, Songlin Zhou, Xiaohong Kong, Shiqing Feng, Shiqing Feng, Xue Yao, Xue Yao   +19 more
doaj   +1 more source

Acute and Sub-chronic Anticonvulsant Effects of Edaravone on Seizure Induced by Pentylenetetrazole or Electroshock in Mice, Nitric Oxide Involvement [PDF]

Iranian Journal of Medical Sciences, 2023
Background: Edaravone is an anti-stroke medication that may have nitric oxide (NO) modulating properties. This study evaluated the role of NO in the acute and sub-chronic anticonvulsant effects of edaravone in murine models of seizures induced by ...
Leila Moezi, Fatema Pirsalami, Mona Dastgheib, Somayeh Oftadehgan, Azar Purkhosrow, Elahe Sattarinezhad   +5 more
doaj   +1 more source

Edaravone Dexborneol Treatment Attenuates Neuronal Apoptosis and Improves Neurological Function by Suppressing 4-HNE-Associated Oxidative Stress After Subarachnoid Hemorrhage

Frontiers in Pharmacology, 2022
Edaravone dexborneol is a novel neuroprotective drug that comprises edaravone and (+)-borneol in a 4:1 ratio. Phase II and III studies have demonstrated that Chinese patients treated with edaravone dexborneol within 48 h of AIS onset have better ...
Qian Chen, Yichen Cai, Xiaoyu Zhu, Jing Wang, Feng Gao, Mingfeng Yang, Leilei Mao, Zongyong Zhang, Baoliang Sun   +8 more
doaj   +1 more source